CE Marked Class III medical device within the Revitrane hyaluronic acid dermal filler range.
Manufactured under ISO 13485 Compliant quality management system for medical devices.
Produced in GMP Compliant facilities operated by BR PHARM Co., Ltd.
Uses high Quality, pharmaceutical Grade, non Animal hyaluronic acid raw material.
CE Marked Class III medical device within the Revitrane hyaluronic acid dermal filler range.
Manufactured under ISO 13485 Compliant quality management system for medical devices.
Produced in GMP Compliant facilities operated by BR PHARM Co., Ltd.
Uses high Quality, pharmaceutical Grade, non Animal hyaluronic acid raw material.
Minimised BDDE cross Linking rate with advanced BDDE residual cleaning, often described by distributors as BDDE not detected.
Description
Revitrane Premium Q is a high-cohesivity, biphasic, cross-linked hyaluronic acid dermal filler specifically developed for non-surgical rhinoplasty and precise nasal contouring. Containing 20 mg/mL of cross-linked hyaluronic acid in a strong, elastic particle gel, it is designed to reshape the nose by smoothing the bridge, lifting the tip, correcting small humps and asymmetries, and refining the overall nasal profile. The filler’s very high cohesivity significantly reduces the risk of migration, allowing it to maintain sharp definition and stable shape for 8–10 months. Supplied as a 1 x 1 ml pre-filled syringe, Revitrane Premium Q combines advanced cross-linking and BDDE-cleansing technology with comfortable injection handling to deliver natural-looking, long-lasting results when used by appropriately trained medical professionals.
Bnefits
Specifically created for non-surgical rhinoplasty and nasal contouring.
High cohesivity gel that settles in place and maintains its shape with minimal migration.
In some distributor descriptions, gentle contouring of medium-depth wrinkles and cheek area, although its primary indication is nose modeling; deeper volumisation elsewhere is generally better suited to Revitrane Premium or Premium Sub-Q.
Biphasic gel structure with strong elastic particles for contouring and projection.
Cross-linking agent: BDDE (1,4-Butanediol diglycidyl ether), with minimised cross-linking rate and advanced residual BDDE cleaning (often described as BDDE not detected in distributor specifications).
Physiological, sterile buffer solution/vehicle as specified in the official instructions for use.
No added lidocaine in most UK/EU-distributed presentations (supplied as a plain HA filler without local anaesthetic).
High-cohesivity filler engineered to stay in place, reducing migration risk in the nasal region.
Optimised viscoelastic properties for structural support and sharp contour definition.
Integrates with surrounding tissues while maintaining stable three-dimensional shape for nasal profile correction.
Class III CE-marked injectable medical device intended primarily for nasal bridge and tip reshaping.
Part of the Revitrane HA line, manufactured using advanced cross-linking and purification technologies to achieve low endotoxin levels and uniform HA structure.
Packaging
1 x 1 ml pre-filled sterile glass syringe of Revitrane Premium Q.
Typically supplied with 2 x 25G 1/2" JBP needles (as specified by multiple distributors).
Syringe and needles packaged in a sterile blister tray within an outer printed carton.
Carton labelled with product name, volume, batch/lot number, expiry date, CE mark, manufacturer (BR PHARM Co., Ltd.) and professional-use-only statements.
Ergonomic syringe grip and thin-walled needles to support precise, controlled injection during non-surgical rhinoplasty.
Usage
For professional use only by suitably trained and qualified healthcare practitioners experienced in dermal fillers and non-surgical rhinoplasty, with detailed knowledge of nasal vascular anatomy and complication management.
Conduct a thorough medical history and facial assessment, including prior nasal surgery, breathing issues, allergies, medications (especially anticoagulants), and previous filler treatments. Obtain informed consent and discuss realistic expectations and potential risks, including rare but serious vascular and visual complications.
Inspect the packaging and syringe; do not use if sterility has been compromised, the blister is damaged, or the product is expired or improperly stored.
Cleanse and disinfect the nasal and surrounding areas using an appropriate skin antiseptic, avoiding eye and mucosal contact.
Attach a suitable sterile 25G 1/2" needle or appropriate cannula securely to the syringe, expelling air and a small droplet of gel before injection.
Inject slowly in small amounts into the recommended tissue planes for non-surgical rhinoplasty (typically supraperiosteal or deep subcutaneous over the nasal dorsum and tip), using appropriate techniques such as linear threading or depot injections according to training and current best practice.
Aspiration and use of cannulas may be considered as part of a risk-reduction strategy, but do not replace careful anatomical knowledge and conservative technique.
Carefully monitor tissue blanching, pain and colour changes during injection; stop immediately if signs of vascular compromise occur.
After injection, gently mold and shape the filler with light fingertip pressure to achieve the desired nasal contour; avoid aggressive massage that could displace the product.
Provide detailed aftercare advice: advise the patient to avoid touching or pressing on the nose, avoid wearing heavy glasses on the bridge in the immediate post-treatment period, and refrain from vigorous exercise, extremes of heat or cold, and alcohol for 24–48 hours.
Inform patients to seek urgent medical attention if they experience severe pain, sudden discolouration, visual disturbances, or any unusual or worsening symptoms.
Dispose of needles, cannulas and any used syringes safely in approved sharps containers in accordance with local regulations.
Contraindications
Known hypersensitivity or allergy to hyaluronic acid or any of the excipients in the product.
History of severe anaphylactic reactions or multiple severe allergies.
Presence of active infection, inflammation, skin disease or compromised tissue at or near the intended nasal injection sites.
Previous permanent or semi-permanent filler in the nose or surrounding areas, unless the practitioner is fully confident in the safety of combining products.
Uncontrolled bleeding disorders or concurrent use of significant anticoagulant/antiplatelet therapy without careful risk-benefit assessment.
Pregnancy and breastfeeding, as safety data are lacking and treatment is generally not recommended.
Severe autoimmune diseases or marked immunosuppression where injectable aesthetic treatments may carry heightened risk, unless undertaken with specialist input.
Intravascular injection is strictly contraindicated; do not inject into blood vessels or in a manner that risks intravascular placement, particularly in high-risk nasal and periocular vascular territories.
Adverse Effects
Common, transient local reactions at injection sites such as redness, swelling, tenderness, pain, bruising, itching and local warmth; these usually resolve within a few days to two weeks.
Temporary irregularities, small lumps or asymmetry that may improve spontaneously, with gentle molding, or after follow-up adjustment.
Less common complications including local infection, prolonged edema, delayed-onset nodules or inflammatory reactions.
Vascular occlusion due to inadvertent intravascular injection or external compression, potentially leading to intense pain, blanching, livedo, tissue ischemia and necrosis if not rapidly identified and treated; this is a medical emergency and may require hyaluronidase and other urgent interventions.
Extremely rare but serious events associated with filler injections in the nasal and periocular region, such as visual disturbances, blindness, stroke-like symptoms or neurological deficits due to embolisation of filler material.
Immediate or delayed hypersensitivity reactions, including rare anaphylactic responses.
Any unusual, persistent or severe adverse event should prompt urgent clinical review and, where appropriate, reporting to relevant regulatory authorities.
Storage Conditions
Store in the original, sealed packaging at a controlled temperature, generally between 2°C and 25°C as indicated in the product leaflet; do not freeze.
Protect from direct sunlight, excessive heat and moisture.
Do not use if the product has been frozen, overheated, visibly damaged or stored outside of the recommended temperature range.
Keep out of the reach of children and unauthorised individuals.
Single-use sterile device: once opened and used on a patient, any remaining filler must be discarded and must not be reused.
Duration
Most distributors report that results with Revitrane Premium Q last approximately 8\u201310 months in the nasal area, depending on injection technique, volume used, patient metabolism, lifestyle and local tissue characteristics.
Onset
Immediate reshaping and contouring of the nose are seen at the time of injection, with final results typically evident once initial swelling and any minor bruising have resolved over several days; gel integration and tissue hydration can continue to refine the appearance over subsequent weeks.
